Trump Deal Lowers Price of Popular Weight-Loss Drugs By Nearly 90 Percent

Lower prices will be available starting in January for direct-pay customers, and in July for Medicare and Medicaid programs.

President Donald Trump, joined by members of the pharmaceutical industry and administration officials, delivers remarks on lowering drug prices in the Oval Office at the White House in Washington, DC, on Nov. 6, 2025. Andrew Harnik/Getty Images

Americans will have access to Zepbound and Wegovy at reduced prices starting in 2026. 

The wildly popular treatments for diabetes and obesity will be available to consumers at a nearly 90 percent discount in January, under an agreement negotiated by the Trump administration with Eli Lilly and Novo Nordisk.